Journal Information
Vol. 43. Issue. 6.November - December 2023
Pages 663-806
Visits
1369
Vol. 43. Issue. 6.November - December 2023
Pages 663-806
Letters to the Editor - Comments on published articles
Full text access
Kluyvera ascorbata sepsis in a patient on hemodialysis
Sepsis por Kluyvera ascorbata en un paciente en hemodiálisis
Visits
1369
Catalina Ulloa-Clavijoa,
Corresponding author
catalinaulloac@hotmail.com

Corresponding author.
, Ana Suárez-Laurésa, Guillermo Viejo De la Cuadrab, Luis Galvánc, Claudia Martínez-Suáreza, Emilio Sánchez-Álvareza
a Servicio de Nefrología, Hospital de Cabueñes, Gijón, Asturias, Spain
b Servicio de Microbiología, Hospital de Cabueñes, Gijón, Asturias, Spain
c Unidad de Hemodiálisis, Hospital de Jove, Gijón, Asturias, Spain
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Dear Editor,

In patients with chronic kidney disease on renal replacement therapy, after cardiovascular disease, infections are the second leading cause of hospitalisation and death.1 Vascular access is the main source of bacteraemia, and in this group of patients sepsis the risk of death is increased 100 times.2 The most common micro-organism involved in up to 80% of haemodialysis catheter infections is Staphylococcus aureus, but other germs, including non-fermenting Gram-negative bacilli, have also been reported.3 There are several pathogens of the Enterobacteriaceae family, including Kluyvera strains,4 which rarely affect humans, but when they do, they can cause severe infection and death. We believe it is of interest to present the case of a patient on haemodialysis with Kluyvera ascorbata (K. ascorbata) infection which, to our knowledge, has not been previously reported.

Case report

This was a 66-year-old woman, partially dependent for basic activities of daily living, smoker of 20 cigarettes a day, with a history of obesity, chronic obstructive pulmonary disease, hypertension, treated and cured cervical adenocarcinoma, urinary sepsis and long-standing type 2 diabetes mellitus (DM2) with micro- and macrovascular damage which had led to chronic diabetic kidney disease and the initiation of haemodialysis one year before. A right brachiocephalic arteriovenous fistula had been created, but did not mature. A right jugular tunnelled catheter was then inserted, but had been replaced five months ago due to dysfunction. She was referred from a dialysis centre for sudden onset of hypotension and dyspnoea with desaturation after sealing of the branches of the dysfunctional catheter with urokinase. As anaphylactic reaction was suspected, the patient was given adrenaline 5 mg by nebulisation and 0.5 mg intravenously, hydrocortisone 200 mg intravenously, dexchlorpheniramine 5 mg/mL intravenously and ventilatory support. Blood tests showed hyperkalaemia of 6.8 mEq/l as the only notable finding and a chest CT scan ruled out lung disease.

When the patient arrived at our centre, the referral hospital for the area, she was hypotensive and tachycardic and with a low level of consciousness. A greenish exudate was observed at the catheter entry orifice, so it was decided to remove it, sending the tip for culture, as well as taking samples for blood and urine cultures, and inserting a temporary catheter in the left jugular vein. A repeat blood test showed leucocytes 18,060/mL (93.4% neutrophils), CRP 232.5 mg/dl (normal <5) and procalcitonin which peaked at 175 ng/mL (normal <0.50), and the serum albumin was 3 g/dl. She was initially started on empirical antibiotic therapy with meropenem and vancomycin. At 72 h, we were informed of the growth of K. ascorbata (>15 colonies/catheter) sensitive to carbapenems and aminoglycosides in blood cultures and catheter tip, and Enterobacter cloacae sensitive to quinolones in urine. Treatment was continued with gentamicin and ciprofloxacin with very good progress.

Discussion

This is the first reported case of a haemodialysis patient with K. ascorbata infection. Our patient had several risk factors for developing catheter-related bacteraemia, including age, DM, hypertension, hypoalbuminaemia and atherosclerosis, and the catheter had been in place for five months; we know that the risk of infection in the first six months after insertion is 46%.5 Among the clinical characteristics of catheter-related bacteraemia, we should highlight the dysfunction of the catheter, which was initially observed6 and a thrombosis was suspected, for which she was given urokinase. The germ isolated, K. ascorbata, is a Gram-negative, glucose-fermenting, oxidase-negative, catalase-positive bacillus found in some foods of animal origin, water, plants and hospital toilets and is it is common in the respiratory and digestive tract. Described in 1936 by Kluyver and Niel, it was initially considered a benign germ, but its pathogenic capacity was identified years later.4–7 The few reported cases (45 to date) have been in immunocompromised patients, pregnant women and children,8 making it an opportunistic germ. Our patient had an immune dysfunction mainly as a result of chronic kidney disease and DM, which put her at risk for infections; it is important to remember that patients with DM have asymptomatic bacteriuria frequently, this being the case with our patient. Case series document that the germ has been isolated in urine, peritoneal fluid, the mouth and blood; in our case, it was isolated from the haemodialysis catheter which was the gateway to the bloodstream and led to sepsis. In terms of treatment, it is known that cephalosporins, fluoroquinolones, aminoglycosides, tetracycline, aztreonam and carbapenems are the most commonly used drugs. We initially used meropenem and then gentamicin; the microorganism was resistant to third generation cephalosporins as documented in one case.9 However, we would like to emphasise that the first step to be taken in the event of a severe haemodialysis catheter infection is as recommended in the guidelines the removal of the catheter.10 Early and comprehensive management of K. ascorbata catheter-related bacteraemia was key to the patient’s survival.

Funding

No funding was received for this study.

References
[1]
R. Saran, B. Robinson, K.C. Abbott, L.Y. Agodoa, P. Albertus, J. Ayanian, et al.
US renal data system 2016 annual data report: epidemiology of Kidney Disease in the United States.
Am J Kidney Dis, 69 (2017), pp. A7-A8
[2]
G. Taylor, D. Gravel, L. Johnston, J. Embil, D. Holton, S. Paton, Canadian Nosocomial Infection Surveillance Program; Canadian Hospital Epidemiology Committee.
Incidence of bloodstream infection in multicenter inception cohorts of hemodialysis patients.
Am J Infect Control, 32 (2004), pp. 155-160
[3]
A. Ishani, A.J. Collins, C.A. Herzog, R.N. Foley.
Septicemia, access and cardiovascular disease in dialysis patients: The USRDS Wave 2 study.
Kidney Int, 68 (2005), pp. 311-318
[4]
A.J. Kluyver, C.B. van Niel.
Prospects for a natural system of classification of bacteria.
Zentralbl Bakteriol Parasitenkd Infektionskr Hyg, 95 (1936), pp. 369-403
[5]
F. Delistefani, M. Wallbach, G.A. Müller, M.J. Koziolek, C. Grupp.
Risk factors for catheter-related infections in patients receiving permanent dialysis catheter.
BMC Nephrol, 20 (2019), pp. 199
[6]
L.M. Miller, E. Clark, C. Dipchand, S. Hiremath, J. Kappel, M. Kiaii, Canadian Society of Nephrology Vascular Access Work Group, et al.
Hemodialysis tunneled catheter-related infections.
Can J Kidney Health Dis, 3 (2016),
[7]
T. Brooks, S. Feldman.
Central venous catheter infection in a child: case report and review of Kluyvera infection in children.
[8]
J. Lee, J.H. Hwang, D.S. Jo, H.S. Lee, J.H. Hwang.
Kluyvera ascorbata as a pathogen in adults and children: clinical features and antibiotic susceptibilities in a single center study.
Jpn J Infect Dis, 72 (2019), pp. 142-148
[9]
Y. Mutoh, T. Kobe, T. Hirano, T. Ichihara, H. Takenaka, T. Niinomi, et al.
The first case of third-generation cephalosporins resistant Kluyvera ascorbata biliary tract infection in Japan: a case report and review of the literature.
IDCases, 15 (2019), pp. e00498
[10]
J. Ibeas, R. Roca-Tey, J. Vallespín, T. Moreno, G. Moñux, A. Martí-Monrós, por el Grupo Español Multidisciplinar del Acceso Vacular (GEMAV), et al.
Guía Clínica Española del Acceso Vascular para Hemodiálisis.
Copyright © 2021. Sociedad Española de Nefrología
Download PDF
Idiomas
Nefrología (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?